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ABSTRACT
Background and Objectives: Acute heart failure (AHF) is associated with a poor prognosis and it requires repeated hospital-
izations. However, there are few studies on the characteristics, treatment and prognostic factors of AHF. The aims of this study 
were to describe the clinical characteristics, management and outcomes of the patients hospitalized for AHF in Korea. Sub-
jects and Methods: We analyzed the clinical data of 3,200 hospitalization episodes that were recorded between June 2004 
and April 2009 from the Korean Heart Failure (KorHF) Registry database. The mean age was 67.6±14.3 years and 50% of the 
patients were female. Results: Twenty-nine point six percent (29.6%) of the patients had a history of previous HF and 52.3% 
of the patients had ischemic heart disease. Left ventricular ejection fraction (LVEF) was reported for 89% of the patients. The 
mean LVEF was 38.5±15.7% and 26.1% of the patients had preserved systolic function (LVEF ≥50%), which was more preva-
lent in the females (34.0% vs. 18.4%, respectively, p<0.001). At discharge, 58.6% of the patients received beta-blockers (BB), 
53.7% received either angiotensin converting enzyme-inhibitors or angiotensin receptor blockers (ACEi/ARB), and 58.4% re-
ceived both BB and ACEi/ARB. The 1-, 2-, 3- and 4-year mortality rates were 15%, 21%, 26% and 30%, respectively. Multivari-
ate analysis revealed that advanced age {hazard ratio: 1.023 (95% confidence interval: 1.004-1.042); p=0.020}, a previous history 
of heart failure {1.735 (1.150-2.618); p=0.009}, anemia {1.973 (1.271-3.063); p=0.002}, hyponatremia {1.861 (1.184-2.926); p= 
0.007}, a high level of serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) {3.152 (1.450-6.849); p=0.004} and 
the use of BB at discharge {0.599 (0.360-0.997); p=0.490} were significantly associated with total death. Conclusion: We pres-
ent here the characteristics and prognosis of an unselected population of AHF patients in Korea. The long-term mortality rate 
was comparable to that reported in other countries. The independent clinical risk factors included age, a previous history of 
heart failure, anemia, hyponatremia, a high NT-proBNP level and taking BB at discharge. (Korean Circ J 2011;41:363-371)
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Introduction
Acute Heart failure (AHF) is one of the most common con-
ditions encountered in emergency care and AHF is associated 
with hospitalization and a poor prognosis.1) Even though the 
prevalence of AHF is increasing and its clinical outcome is fa-
tal at its worst, there is limited data on its epidemiology, treat-
ment and prognosis.2) Many hospital-based and community-
based registries have elucidated the clinical characteristics, th-
erapeutic modalities and outcomes of patients with heart fail-
ure.3)4) However, there have been no large-scale observational 
studies to evaluate the clinical features of Korean patients with 
AHF.
Several markers of a poor prognosis have been described for 
patients with heart failure. The widely recognized risk factors 
include age, ischemic heart disease, a reduced left ventricular 
ejection fraction (LVEF) and renal dysfunction.5) In addition, 
anemia, hyponatremia, male gender and diabetes have been 
associated with a poor prognosis.6)7) The values of these prog-
nostic factors in AHF patients are less well documented. The 
Korean Heart Failure (KorHF) Registry is a nationwide ob-
servational, prospective, multi-centre study on AHF. It is the fi-
rst multi-center registry of consecutive AHF patients accord-
ing to the Korean AHF criteria. Our objectives were to inves-
tigate the etiology, clinical characteristics, treatment modali-
ties, morbidity, mortality and prognostic markers of AHF.
Subjects and Methods
Criteria and enrolment
Between June 2004 and April 2009, the data on the clinical 
status and in-hospital outcomes of patients was obtained fol-
lowing a review of the registry data from 24 hospitals in Korea. 
The participating centers were evenly located nationwide in 
proportion to the population they serve. Heart failure was 
diagnosed on admission according to the Framingham cri-
teria.7) The institutional review board or ethics committee at 
each participating hospital approved the study protocol, and 
the patients gave their written informed consent prior to st-
udy entry.
Data collection
The patient demographic and baseline characteristics, the 
underlying diseases, the clinical presentation, treatments and 
outcomes from the initial presentation through hospitaliza-
tion and at discharge were recorded. The data was entered 
into the KorHF Registry database via a Web-based electronic 
data capture system that included an electronic case report 
form. The diagnosis of heart failure was required to be con-
firmed at the time of a patient’s discharge. Morbidity and the 
in-hospital and long-term mortality were also documented. 
Data collection and audition were performed by the KorHF 
Registry Steering Committee at The Korean Society of Heart 
Failure.
Etiology of heart failure
We attempted to determine the etiology of heart failure and 
identify the demographic characteristics, clinical variables 
and biochemical markers that had prognostic impact. We com-
pared the long-term mortality in relation to age, gender, the 
body mass index (BMI) and the previous medical history. A 
history of hypertension, dyslipidemia and/or diabetes melli-
tus was recorded if documented by the physician in the ad-
mitting notes, and if the clinical diagnoses and criteria con-
formed to the Framingham’s criteria. The use of beta-blockers 
(BB), angiotensin converting enzyme-inhibitors (ACEi) and/
or angiotensin receptor blockers (ARB) at discharge was as-
sessed for their impact on the prognosis. We further evaluated 
the effect of the left ventricular systolic function on survival, 
the clinical presentation and the cause of heart failure. The bio-
chemical variables included in the analysis were anemia (blo-
od hemoglobin <12.0 g/dL), hyponatremia (sodium <135 mmol/ 
L), azotemia (serum creatinine ≥2.0 mg/dL), hypocholester-
olemia (cholesterol <160 mg/dL) and the N-terminal pro-B-
type natriuretic peptide (NT-proBNP) level at admission (over 
1,000 pg/mL). 
Follow-up information
Research coordinators guided by documented definitions 
used standardized report forms to collect the follow-up events 
until October 2009. The medical records were reviewed wh-
enever possible when patients required repeat hospitaliza-
tion. In addition to patient telephone interviews, the referring 
physicians and institutions were contacted when necessary for 
additional information. We obtained information on patient 
survival and hospital readmission for heart failure. Events 
related to heart failure were defined as admission for heart 
failure deterioration, transplantation or all-cause death.
Statistical analysis
The continuous variables are expressed as means±standard 
deviation (SD). Group comparisons were based on the Stu-
dent’s t-test or the χ2 test as appropriate. Survival function esti-
mates were derived using the Kaplan-Meier method, and dif-
ferences were tested using the log-rank test. Predictors of sur-
vival were identified using univariate and multivariate Cox 
proportional hazard regression analyses. 
The candidate independent variables included age, gender, 
a previous diagnosis of heart failure, the systolic blood pres-
sure, the heart rate, the BMI, anemia, the ejection fraction and 
the systolic heart failure medications at discharge. The entry 
criterion for the multivariate analysis was a p<0.05, which 
was considered statistically significant. The results are pre-
sented as means, SD, percentages {95% confidence interval 
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(CI)} and hazard ratios (95% CI) where appropriate. All the 
analyses were conducted using the Statistical Package for the 
Social Sciences (SPSS) 15.0 statistical software (SPSS Inc.). 
Results
The KorHF Registry database included 3,200 admission 
episodes for heart failure at 24 centers. The mean observa-
tional period was 1.7 years (from 0.1 to 4.9 years) from June 
of 2004 to April of 2009, and the follow-up rate was 81%. 
 
Demographic and clinical characteristics 
The patient demographics and the characteristics of the past 
medical history for the patient episodes of heart failure are sum-
marized in Table 1. Among the 3,200 patients, 1,612 (50.4%) 
were over 70 years old. The average age was 67.6±14.3 years 
old and the women were significantly older than the men 
(mean age: 70.7±13.5 vs. 64.5±14.5 years, p<0.0001) and the 
women had a lower BMI. Twenty-nine point six percent (29.6%) 
of the patients had a prior history of heart failure. In addi-
tion, 46.5% of the patients had a history of hypertension, 
and a history of diabetes, stroke and chronic renal disease was 
present in 30.5%, 18.9% and 9.2%, respectively. The underly-
ing causes of heart failure were as follows: ischemic heart 
disease (52.3%), myocardial infarction or coronary heart dise-
ase in 1,194 patients (77.3%), valvular heart disease (12.7%) 
and cardiomyopathy (26.5%). Idiopathic dilated cardiomy-
opathy was present in 747 patients (87.9%). However, the oth-
er clinical features were similar between the two groups, ex-
cept for a higher prevalence of ischemic heart disease and val-
vular heart disease as the underlying disease in the female 
patients. 
The clinical characteristics of the patients at presentation are 
shown in Table 2. Acute episodes of heart failure were gen-
erally associated with dyspnea. Upon admission, 22.9% of the 
patients experienced dyspnea at rest (NYHA functional class 
IV criteria), whereas 10.5% of patients experienced other sym-
ptoms of heart failure (NYHA class I). However, 15.5% and 
51.1% of the patients had symptoms of NYHA class II and 
III, respectively. The dyspneoic symptoms and blood pressure 
levels were similar in both gender groups. Hypotension (sys-
tolic BP <90 mmHg) was identified in 4.3% of the admissions 
and the rate was similar for females and males. 
The laboratory findings of the patients at presentation are 
summarized in Table 2 and 3. The abnormal blood chemis-
try and the markers presented with AHF on admission were 
as follows: hyponatremia (18.0%, a level of creatinine <135 
mM), anemia (41.4%, a level of hemoglobin <12 mg/dL), 
azotemia (14.9%, a level of creatinine ≥2.0 mg/dL) and hy-
pocholesterolemia (51.5%, a level of total cholesterol <160 
mg/dL). 
We identified LVEF in 2,843 (88.8%) patients in the pres-
ent study: the mean LVEF was 38.5±15.7%, and preserved 
systolic function, which was defined as a LVEF >50%, was 
evident in 743 patients (26.1%). The female patients pre-
sented with a higher LVEF (female vs. male: 41.6±16.1% vs. 
35.4±14.7%, respectively, p<0.001) and a higher prevalence 
of heart failure with preserved systolic function (34.0% vs. 
18.3%, respectively, p<0.001).
Intravenous diuretic infusions/boluses were given to 68.6% 
of the patients, and 35.8% received intravenous nitrates. Ino-
tropic treatment was used in 21.7% of the patients, and 22.4% 
Table 1. Demographic and clinical features 
 Characteristics Total, n=3,200 Female, n=1,600 (50%) Male, n=1,600 (50%) p*
Age (year, mean±SD) 67.6±14.3 70.7±13.5 64.5±14.5 <0.001
BMI (kg/m2) 23.2±4.00 23.0±4.20 23.4±3.80 0.009 
Previous medical history (%)
Heart failure 871 (29.6) 453 (30.4) 418 (28.7) 0.313 
Hypertension 1,486 (46.5) 787 (49.2) 699 (43.7) 0.002 
Diabetes 975 (30.5) 489 (30.6) 486 (30.4) 0.927 
Stroke 299 (18.9) 137 (18.0) 162 (19.8) 0.361 
Chronic renal disease 295 (9.2)0 134 (8.4)0 161 (10.1) 0.970 
Chronic pulmonary disease 104 (3.5)0 43 (2.9)0 61 (4.2)0 0.055 
Underlying disease (%)
Ischemic heart disease 1,544 (52.3) 828 (53.6) 716 (46.4) <0.001
Hypertension 1,143 (36.7) 596 (38.1) 547 (35.3) 0.103 
Cardiomyopathy 760 (26.5) 351 (24.3) 409 (28.8) 0.007 
Valvular heart disease 407 (12.7) 255 (16.4) 152 (9.7)0 <0.001
Myocarditis 22 (0.7)0 8 (0.6)0 14 (1.0)0 0.187 
Infiltrative disease 12 (0.4)0 5 (0.3)0 7 (0.5)0 0.545 
*Comparison between the female and male groups. BMI: body mass index
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of these patients received two or more inotropes. Dobuta-
mine (17.2%) and dopamine (9.5%) were the most common-
ly administered inotropes. Few patients received noradrena-
line (0.9%) or mirlinone (0.2%). Inotropic agents were used 
more frequently in the males than in the females (59.3% vs. 
62.4%, respectively, p=0.001). For critical care, 1,330 patients 
(37.7%) stayed at intensive care units during hospitalization, 
and 247 patients (7.1%) received mechanical ventilator assist-
ance. Hemodialysis was performed in 4.1% of the patients. He-
modynamic monitoring was performed in 5.9% of the pa-
tients and intraaortic balloon pump was used in 3.3% of the 
patients.
Either ACEi or angiotensin-II receptor blockers (ARB) 
were prescribed at discharge for 53.7% of the patients. BBs 
and spironolactone were administered to 58.6% and 53.1% 
of the patients, respectively. One of both, BBs or ACEi/ARB, 
was prescribed to 58.4% of the patients. There was no differ-
ence in discharge medication between the two gender gr-
oups (Table 2). 
Clinical outcomes and predictors 
Of the 3,200 consecutive admitted patients with heart fail-
ure, 2,973 (92.9%) of them were discharged alive. During the 
follow-up period (mean±SD: 1.7±1.2 years), 625 patients 
(19.5%) died. The mortality rate during hospitalization was 
6.4%. The cumulative survival rates for the study patients af-
Table 2. Clinical presentation and the hospital course
Characteristics Total Female, n=1,600 (50%) Male, n=1,600 (50%) p*
Clinical findings
SBP (mmHg) 130.5±30.200 131.7±30.500 129.3±29.80 0.240 
DBP (mmHg) 77.9±18.00 77.7±17.40 78.1±18.7 0.517 
Hypotension (SBP <90 mmHg) (%) 135 (4.3) 65 (4.2)0 70 (4.5) 0.622 
PR (bpm) 91.2±25.40 91.5±25.80 91.0±25.0 0.615 
NYHA functional class at admission (%)
I 0,283 (10.5) 123 (9.1)0 160 (12.0) NS
II 0,419 (15.5) 196 (14.5) 223 (16.7) NS
III 1,376 (51.1) 685 (50.5) 691 (51.6) NS
IV 0,616 (22.9) 352 (26.0) 264 (19.7) NS
Echo results 
LVEF (%, mean) 38.5±15.70 41.6±16.10 35.4±14.7 <0.001
LVEF ≥50% (%) 0,743 (26.1) 481 (34.0) 262 (18.3) <0.001
Lab. Findings
Sodium (mM) 138.1±26.400 138.1±5.4000 138.1±4.900 0.892 
Hemoglobin (mg/dL) 12.4±5.500 11.7±2.100 13.2±2.40 <0.001
Creatinine (mg/dL) 1.5±1.20 1.4±1.20 1.6±1.4 <0.001
Total-cholesterol (mg/dL) 164.1±47.100 167.6±48.700 158.7±43.90 <0.001
NT-proBNP (ng/L) 8,461±96,002 9,456.0±10,358.6 7,680.1±9,341.5 <0.001
Hospital management (%)
Diuretics IV 1,982 (68.1) 1,009 (68.6) 973 (67.5) 0.518 
Nitrate IV 1,042 (35.8) 520 (35.4) 522 (36.2) 0.632 
Inotropic agents 0,711 (21.7) 285 (59.3) 346 (62.4) 0.001 
Dobutamine 0,502 (17.2) 225 (15.3) 277 (19.2) 0.005 
Dopamine 0276 (9.5) 118 (8.0)0 158 (11.0) 0.007 
Hemodynamic monitoring 0171 (5.9) 84 (5.7)0 87 (6.0) 0.707 
IABP 0,96 (3.3) 41 (2.8)0 55 (3.8) 0.121 
Medication at discharge (%)
Beta-blocker 1,109 (58.6) 567 (58.7) 542 (58.4) 0.926 
ACEi/ARB 0,648 (53.7) 321 (52.5) 327 (54.9) 0.417 
Aldosterone antagonist 0,913 (53.1) 456 (52.4) 457 (53.8) 0.562 
*Comparison between the female and male group. SBP: systolic blood pressure, DBP: diastolic blood pressure, PR: pulse rate, NYHA: New 
York Heart Association, LVEF: left ventricular ejection fraction, NT-proBNP: N-terminal pro-B-type natriuretic peptide, IABP: intraaortic 
balloon pump, ACEi: angiotensin converting enzyme-inhibitors, ARB: angiotensin receptor blocker
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ter discharge at 1, 2, 3 and 4 years were 85%, 79%, 74% and 
70%, respectively, which were similar between both gender 
groups (Fig. 1). The event-free survival rates at 1, 2, 3 and 4 
years were 67%, 56%, 47% and 41%, respectively. Heart tr-
ansplantation was performed in 0.9% (31 patients) of the pa-
tients and 24.6% (866 patients) were re-hospitalized. The de-
mographic and clinical variables associated with all cause 
mortality are summarized in Table 3. 
Univariate analysis for the current risk variables showed 
that an advanced age, a low BMI (<23 kg/m2, median value), 
a prior history of heart failure, a non-ischemic origin of heart 
failure, low blood pressure, dyspnea at rest on admission (NY-
HA functional class IV), hyponatremia (<135 mM), anemia 
(hemoglobin <12 g/dL), azotemia (creatinine >2.0 mg/dL), 
low cholesterol (total cholesterol <160 mg/dL) and a high pl-
asma NT-proBNP level (≥1,000 ng/dL) tended to be associ-
ated with an increase in subsequent all-cause mortality, while 
a prescription of BB and/or ACEi/ARB was related with bet-
ter clinical outcomes (Table 4). 
On the basis of data gathered from all the patient episodes 
with AHF, multivariate analysis identified an advanced age, 
previous heart failure, anemia, hyponatremia and a high 
NT-proBNP level showed a tendency of increased subsequ-
ent all-cause mortality, but a prescription of BB at discharge 
was associated with improved clinical outcomes. The multiva-
riate odds ratios (ORs) and corresponding 95% CIs for all-
Fig. 1. The five-year follow-up results according to different gen-
der. The five-year survival rate was 61% and 69% for the male 
(red line) and female (blue line), respectively.
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Table 3. Clinical factors and predictors for the long-term clinical outcomes on univariate analysis
 Characteristics Total Expired, n=652 (19.6%) Alive, n=2,571 (80.4%) HR 95% CI p*
Age (mean) 067.6±14.3 071.6±13.1 066.6±14.5 1.027 1.021-1.034 <0.001
Women (%) 1,600 (50.0) 312 (50.1) 1,285 (50.0) 1.026 0.874-1.205 0.752 
BMI (<23 kg/m2) (%) 1,412 (50.4) 317 (61.9) 1,095 (47.9) 1.781 1.490-2.129 <0.001
Previous heart failure (%) 870 (29.6) 239 (40.9) 631 (26.8) 1.690 1.428-2.001 <0.001
Non-ischemic heart failure (%) 1,410 (47.7) 321 (54.2) 1,089 (46.2) 1.352 1.146-1.596 <0.001
Clinical findings
SBP (mmHg) 130.5±30.2 124.7±30.4 131.9±29.9 0.991 0.988-0.994 <0.001
HR (bpm) 091.2±25.4 091.4±25.1 091.2±25.5 1.000 0.997-1.004 0.780 
Dyspnea at rest (%) 616 (22.9) 155 (25.2) 461 (21.5) 1.499 1.238-1.815 <0.001
Echo results
LVEF (%) 038.5±15.7 038.0±16.2 038.6±15.6 0.995 0.990-1.001 0.113 
LVEF ≥50% (%) 742 (26.1) 137 (26.4) 605 (26.0) 0.948 0.774-1.160 0.601 
Lab. Findings
Hyponatremia (Na <135 mM) 572 (18.0)  180 (31.4) 392 (17.0) 2.226 1.860-2.665 <0.001
Anemia (Hb <12 g/dL) 1,316 (41.4) 346 (55.5) 970 (38.0) 2.021 1.719-2.377 <0.001
Azotemia (Cr ≥2.0 mg/dL) 478 (14.9) 150 (24.3) 328 (13.0) 2.291 1.901-2.761 <0.001
Total-cholesterol (<160 mg/dL) 1,431 (51.1) 318 (58.3) 1,112 (49.3) 1.393 1.169-1.659 <0.001
NT-proBNP ≥1,000 ng/L 1,844 (85.1) 374 (92.6) 1,470 (83.4) 2.425 1.661-3.541 <0.001
Medication at discharge (%)
Beta-blocker 1,109 (58.6) 137 (40.7) 927 (62.5) 0.441 0.352-0.551 <0.001
ACEi/ARB 648 (53.7) 103 (39.3) 545 (57.7) 0.504 0.391-0.650 <0.001
Aldosterone antagonist 913 (53.1) 159 (46.2) 754 (54.8) 0.700 0.563-0.869 0.001 
*Comparison between the expired and alive groups. HR: hazard ratio, CI: confidence interval, BMI: body mass index, SBP: systolic blood pre-
ssure, LVEF: left ventricular ejection fraction, NT-proBNP: N-terminal pro-B-type natriuretic peptide, ACEi: angiotensin converting enzyme-
inhibitors, ARB: angiotensin receptor blocker
Male
Female
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cause death are reported for each mortality risk factor iden-
tified by the Cox Regression model (Table 4). An older age, 
a lower BMI, lower systolic BP, low hemoglobin, low sodium, 
elevated creatinine, the presence of dyspnea at rest and the 
absence of chronic BB use may be considered as the risk fac-
tors of mortality. 
The KorHF Registry is a national observational, prospec-
tive, multi-centre study and it yields new important informa-
tion on the actualities of AHF patients in Korea. It is the first 
population study of the consecutive AHF patients, as charac-
terized according to the Framingham criteria, in 24 medical 
centers in Korea.
Discussion
The age of the patients in our study was high (older than 65 
year-old) and the women were older than the men, which is 
consistent with the findings of previous studies.1-8) The pati-
ents with a prior heart failure history constituted 29.6% of all 
the patients, which was comparable to that of the Japanese 
data from the Heart Institute of Japan-Department of Cardio-
logy (HIJC) registry (33.5%),9) but this was much lower than 
that 75.6% from the American the Acute Decompensated He-
art Failure National Registry (ADHERE) registry.10) This dis-
crepancy may result from ethnic differences or the methods 
of registration. The patients of the KorHFR were consecu-
tively enrolled if they were admitted with a diagnosis of heart 
failure, while the patients of ADHERE were retrospectively 
enrolled.11) 
The predominant cause of heart failure was ischemic heart 
disease. In this study population 52.3% of the patients expe-
rienced heart failure secondary to ischemic heart disease, 
which is considerably lower than the 60-75% reported in the 
clinical trials of Western patients.8) Race and ethnic variations 
may account for the differences in the causes of heart failure 
because the prevalence of ischemic heart disease was also low 
in the studies held in Japan.12) Thus, applying the guidelines 
derived from the study populations containing a higher pro-
portion of patients with ischemic heart disease than the Ko-
rean population should be carefully considered.
A preserved LVEF is a common finding in patients with 
AHF and in elderly heart failure patients.2)13) Among the pa-
tients with information on their LVEF, 26.1% had preserved 
systolic function, which was defined as an LVEF over 50%. 
However, transient systolic heart failure cannot be excluded. 
Echocardiography was not performed in 19.8% of the pa-
tients. The prevalence of heart failure with preserved systolic 
function is comparable to that of other studies based on reg-
istry data.
Although numerous randomized controlled trials have 
shown that ACEis, ARBs and BBs improved the survival of 
patients with heart failure, the proportions of our patients ac-
tually receiving these drugs in the present study were 58.6%, 
53.7% and 58.4%, respectively. These basic agents for the tr-
eatment of heart failure are highly prescribed in Korea, and 
this is comparable to other countries.9)14) During the hospital 
stay, BB, ACEi/ARB, furosemide, digoxin, spironolactone, 
aspirin and oral anticoagulants were frequently initiated to 
the AHF patients. Surprisingly, only the use of BBs at dischar-
ge affected the long-term prognosis, while ACEi/ARBs and 
aldosterone antagonist did not. This appears to suggest that 
AHF and chronic heart failure are two distinct conditions. BB 
and ACEi/ARB therapy were more commonly prescribed to 
our patients than that to the patients included in other studies, 
and these drugs were more often taken by the patients than 
that in a recent survey.15) The use of ARBs was considerably 
higher that that in a recent survey (Table 5). Diuretics were 
used by 68.1% of the patients in our study. Many patients re-
ceived treatment for their precipitating factor and they obvi-
ously did not have significant fluid overload. Spironolactone 
was frequently used since 53.1% of patients with heart failure 
were discharged with this medication. Inotropes are needed 
by AHF patients to support and stabilize the hemodynamics 
if the basic treatment modalities are inadequate. The use of 
inotropes in our study was comparable to that of other stud-
ies.16) Interestingly, dopamine was used in our study twice as 
often as dobutamine. 
Previous studies have demonstrated that advanced age, low 
blood pressure, NYHA associated LV dysfunction and diabet-
es were associated with a poor prognosis for patients with he-
art failure. In addition, several factors such as BNP, C-reac-
tive protein (CRP), impaired renal function and anemia have 
emerged as new predictors associated with a poor prognosis 
in heart failure patients.17) The present study evaluated both 
new (anemia, renal insufficiency, hyponatremia, BNP and 
CRP) and known prognostic factors for heart failure and we 
revealed that anemia, hyponatremia and natreuretic peptide 
were related to the long-term mortality rate. We identified se-
veral demographic and clinical variables as significant pre-
dictors of poor survival on the univariate analysis. Patients 
with older age, a lower BMI less than 23 kg/m2, previous he-
Table 4. Clinical predictors of the clinical outcome on multivariate 
analysis
Characteristics of the patients HR 95% CI p*
Age (mean) 1.023 1.004-1.042 0.020 
Previous heart failure 1.735 1.150-2.618 0.009 
Anemia (Hb <12 mg/dL) 1.973 1.271-3.063 0.002 
Hyponatremia (Na <135 mM) 1.861 1.184-2.926 0.007 
NT-proBNP ≥1,000 ng/L 3.152 1.450-6.849 0.004 
Beta-blocker at discharge 0.599 0.360-0.997 0.049 
*Comparison between the expired and alive groups. HR: hazard ra-
tio, CI: confidence interval, NT-proBNP: N-terminal pro-B-type na-
triuretic peptide
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art failure, lower BP and dyspnea at rest showed poorer clini-
cal outcomes, while heart rate, gender and preserved LV func-
tion did not affect this. However, only age and previous heart 
failure were risk factors of a poor prognosis of AHF. Since 
the women were significantly older than men, male gender 
emerged as a prognostic risk factor only after correcting for 
age. The reported association between a previous history of 
heart failure and a worse prognosis appears meaningful, al-
though it is contrary to a previous study.18) Among the bioche-
mical variables, we found hyponatremia, anemia, renal dys-
function and a high NT-proBNP level in AHF patients were as-
sociated with a poor prognosis. Mortality did not change 
with a declining LVEF in our study, and a LVEF <50% was not 
independently associated with any outcome.19) We also found 
a relationship between higher systolic blood pressure at ad-
mission and better survival on the univariate analysis, but not 
on the multivariate analysis (Table 3 and 4). In contrast to the 
recently reported association between blood pressure and the 
clinical outcome,20) low blood pressure was not a predictor of 
mortality in our patients. The same as in previous reports, ch-
ronic heart failure, anemia, hyponatraemia, and azotemia em-
erged as predictors of mortality in our population.21) The ad-
mission NT-proBNP level was also predictive of the long-
term outcome on multivariable analysis. Indeed, a previous 
study that evaluated the serial or pre-discharge natriuretic pep-
tide measurements in AHF patients revealed that the pre-
discharge natriuretic peptide measurement had better prog-
nostic significance than the admission natriuretic peptide 
levels.22) However, our findings are representative of the value 
of a point measurement of NT-proBNP in an unselected pop-
Table 5. Comparisons of the acute heart failure trials and the KorHF
 Characteristics KorHF ADHERE OPTIME
Age (year, mean) 67.6 72.4 66.5
Gender (women) (%) 50.0 52 47
Previous medical history (%)
Ischemic heart disease 52.3 57 NA
Myocardial infarction 14.2 31 48
Hypertension 46.5 73 68
Diabetes 30.5 44 44
Stroke 18.9 17 NA
Chronic renal disease 9.2 31 NA
Blood pressure
SBP (mmHg) 130.5±30.2 144±32.6 120±18
Hypotension (SBP <90 mmHg) (%) 4.3 02 NA
NYHA functional class at admission (%)
II 16 20 07
III 51 44 46
IV 23 32 47
Echo results
LVEF (%, mean) 38.5±15.7 34.4±16.1 24±8
LVEF >40% (%) 57.5 46 NA
Renal function
Creatinine (mg/dL) 1.5±1.2 1.8±1.6 1.5±0.5
Creatinine (mg/dL) >2.0 mg/dL (%) 15.2 20 NA
Management (%)
Diuretics 68.1 70 90
Nitrate 35.8 26 NA
Beta-blocker 58.6 48 22
ACEi 17.9 41 70
ARB 39.4 12 13
*Comparison between the expired and alive groups. KorHF: Korean Heart Failure, ADHERE: the Acute Decompensated Heart Failure Na-
tional Registry, OPTIME: the Outcomes of a Prospective Trial of Intravenous Milrinone for Excerbations of Chronic Heart Failure study, SBP: 
systolic blood pressure, DBP: diastolic blood pressure, NYHA: New York Heart Association, LVEF: left ventricular ejection fraction, ACEi: 
angiotensin converting enzyme-inhibitors, ARB: angiotensin receptor blocker
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ulation hospitalized for AHF.
This report describes the first population date of all the con-
secutive AHF patients who were characterized according to 
the Framingham criteria and who were from a wide range of 
hospitals in Korea. In contrast to our registry, the patients in 
the randomized clinical trials were younger, the proportion 
of women was smaller than that in real-life and moderate-to-
severe renal dysfunction and significant anemia were the com-
mon exclusion criteria.9)12)22) The all-cause mortality at 12 
months and over the long-term in our study were better than 
that described in the previously published reports.2) Owing 
to the lack of results of long-term follow-up in the ADHERE 
and OPTIME-HF, no comparison can be drawn on the long-
term prognosis. However, the in-hospital and 1-year mortality 
data are similar.10)23) Also, the long-term prognosis was simi-
lar to the Japanese heart failure registries, that is, the HIJC-
HF and JCARD-CARE.9)24) This large-scale, prospective co-
hort study of the KorHF registry with long-term follow-up 
indicated that patients with heart failure in Korea have clini-
cal features that are compatible with those in other countries
Conclusion
The KorHF Registry is a large multi-centre study that in-
cluded a broad spectrum of patients with AHF. This study 
determined the actual nationwide status of heart failure in 
Korea. The registry contains multiple demographic and clini-
cal variables of a large consecutive group of patients admit-
ted to university hospitals. As a whole, the long-term mor-
tality was high and the independent clinical predictors in-
cluded age, a previous history of heart failure, anemia, hypo-
natremia, a high NT-proBNP level and pre-discharge use of 
BB. This data is vital for evaluating the impact of the advanc-
es in diagnostics and therapy on the natural history of heart 
failure in Korea so as to develop improved therapeutic strat-
egies. Further studies are surely warranted to improve heart 
doctors’ adherence to the diagnostic and therapeutic strate-
gies described in the recently published guidelines.
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